Showing results (21-30 of 156) with videos related to
Sort By:
Pageof 16
Der Urologe. Ausg. A|October 15, 2013
[Systemic therapy of metastatic bladder cancer.]M Retz, S C Schmid, M W Kramer, et al.Der Pathologe|July 28, 2010
[EMMPRIN (CD147). A prognostic and potentially therapeutic marker in urothelial cancer]R Nawroth, A Hartmann, P Wild, et al.Urologie (Heidelberg, Germany)|August 4, 2022
[Quality assurance for the treatment of muscle-invasive and metastasized bladder carcinoma in Germany : An initiative of the Working Groups Urological Oncology (AUO) and Internal Oncology (AIO) in the German Cancer Society (DKG)]C H Ohlmann, M Kerkmann, L Holtmann, et al.World Journal of Urology|June 10, 2015
The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancerT Horn, J Laus, A K Seitz, et al.British Journal of Cancer|October 29, 2014
Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapyA Sathe, F Guerth, M V Cronauer, et al.Bladder Cancer (Amsterdam, Netherlands)|December 31, 2016
The Role of PD-L1 Expression and Intratumoral Lymphocytes in Response to Perioperative Chemotherapy for Urothelial CarcinomaF Erlmeier, A K Seitz, G Hatzichristodoulou, et al.Der Urologe. Ausg. A|July 24, 2010
[Continuing medical education in systemic treatment : Are the contents adequately conveyed?]J E GschwendDer Urologe. Ausg. A|September 1, 1996
[Apoptosis--principles and importance of programmed cell death for prostatic carcinoma]J E GschwendDer Urologe. Ausg. A|July 23, 2002
[Specific cellular immunotherapy of renal cell carcinoma. Current status and prospects]M Ringhoffer, J E GschwendDer Urologe. Ausg. A|September 24, 2008
[Value of cystoprostatectomy in locally advanced prostate carcinoma]N Zantl, J E GschwendPageof 16